AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02759237 — intervention group
Intervention type: DEVICE
Intervention: CoreValve System Family
Description: Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK \& EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System \& EnVeo R Loading System - Used to load the TAV onto the delivery system
Study NCT01222533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium medium
Description: Tiotropium inhalation solution medium dose
Study NCT01222533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low
Description: Tiotropium inhalation solution low dose
Study NCT01222533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high
Description: Tiotropium inhalation solution high dose
Study NCT00464555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
Study NCT01222533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18mcg
Description: Tiotropium inhalation powder 18mcg
Study NCT01222533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium placebo
Description: Placebo inhalation solution
Study NCT01947517 — intervention group
Intervention type: DEVICE
Intervention: Parasol Punctal Occluder
Description: Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
Study NCT01947517 — intervention group
Intervention type: DEVICE
Intervention: Superflex Punctal Occluder
Description: Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
Study NCT00867178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo conformal radiation therapy
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study NCT00867178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00867178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00867178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT02276638 — intervention group
Intervention type: DEVICE
Intervention: Specular Microscope Nidek CEM-530
Description: Nidek CEM-530
Study NCT02276638 — intervention group
Intervention type: DEVICE
Intervention: Specular Microscope Konan CELLCHEK XL
Description: Konan CELLCHEK XL
Study NCT03119688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test Product
Description: Micellar cleanser (0.09 ml)
Study NCT03119688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Positive Control
Description: Bar Soap (rubbed for 6 seconds to generate a lather)
Study NCT03119688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference Product
Description: Sterile Water (0.09 ml)
Study NCT03119688 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Treatment
Description: Unwashed area of the forearm
Study NCT01907945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Water Program
Description: Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
Study NCT01907945 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Household education
Description: Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
Study NCT00464555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Will replace antithymocyte globulin in all islet transplantations after the first one
Study NCT00464555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisofylline
Description: An anti-inflammatory that may reduce the rate at which islet cells die.
Study NCT02418845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYM-1219
Study NCT00464555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Maintenance immunosuppressive therapy
Study NCT00464555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Maintenance immunosuppressive therapy
Study NCT02418845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00508274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
Study NCT00508274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
Study NCT01179412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% povidone-iodine
Description: apply 4 times a day for one week
Study NCT01179412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% povidone-iodine
Description: apply 2% povidone-iodine 4 times per day for one week
Study NCT03046368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cover letter
Description: The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
Study NCT06153030 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study NCT02139462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard FBT training
Description: Therapists will receive standard training in Family Based Treatment (FBT)
Study NCT02139462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel FBT training
Description: Therapists will receive a novel training in Family Based Treatment (FBT)
Study NCT01522703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprouts
Description: 100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
Study NCT01522703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Alfalfa Sprouts
Study NCT03899207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training +acupressure
Description: .Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women
Study NCT03899207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training
Description: Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women.
Study NCT04255407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-ONE® therapy
Description: I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
Study NCT04255407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-inflammatory drug
Description: Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
Study NCT01108692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telecardiology
Description: Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups.
Study NCT01108692 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telecardiology
Description: Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups.
Study NCT02992184 — intervention group
Intervention type: DEVICE
Intervention: HCV RNA detection with Genedrive assay
Study NCT03166046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Shortwave Therapy
Description: Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
Study NCT03166046 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pulsed Shortwave therapy
Description: Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
Study NCT04140266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine (DPV) Vaginal Ring (VR)-004
Description: Vaginal ring containing 25 mg of DPV
Study NCT02992184 — intervention group
Intervention type: DEVICE
Intervention: HCV RNA detection with RealTime HCV
Study NCT04140266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Tablet
Description: Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
Study NCT00884559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instruction
Description: Debriefing
Study NCT00884559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: instruction
Description: Debriefing
Study NCT00038298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given 3 times weekly
Study NCT00038298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 719
Description: 50 mg 3 times weekly
Study NCT00038298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGM 719
Description: 200 mg 3 times weekly
Study NCT00038298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 719
Description: 400 mg 3 times weekly
Study NCT00038298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to AMG 719
Description: Placebo dose given 3 times weekly
Study NCT02546505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Front-of-pack nutrition labeling
Description: Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
Study NCT02546505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumer information
Description: Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
Study NCT03217461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CorneaL epithelial autograft
Description: After removal of the recipient's diseased dermoid, a size-match donor epithelial tissue will be obtained from the healthy area of the same eye (corneal epithelial autograft) using femtosecond laser technology, with the goal of closure of bare stromal area by sutured corneal epithelial tissue to ensure the integrity of ocular surface. This closure may also create a microenvironment that stimulates stromal cells' regenerative capacity and regulates their epithelial-mesenchymal transition process.
Study NCT03217461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation
Study NCT03217461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limbal autograft
Description: Simple dermoid excision will be performed, followed by closure of the bare sclera by sutured femtosecond laser-assisted limbal autograft.
Study NCT03217461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation
Study NCT03480295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid 0.4% and Taurine 0.5%
Description: 4 drops /day in addition to the ongoing glaucoma treatment
Study NCT03480295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid 0.2%
Description: 4 drops /day in addition to the ongoing glaucoma treatment
Study NCT00184197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Study NCT00184197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT01114139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study NCT01114139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo
Study NCT01243411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
Study NCT00244907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genistein vs Risedronate
Description: Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
Study NCT00963443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: 2 Sachets of 500 mg Aspirin Complex.
Study NCT00963443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: 2 Sachets of 500 mg Aspirin Complex.
Study NCT00963443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: 2 Sachets of 30 mg Pseudoephedrine
Study NCT00963443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: 2 Sachets of 30 mg Pseudoephedrine
Study NCT00963443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT05317559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: room light
Description: The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
Study NCT01140412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg BID x 5 days
Study NCT01140412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 700/100 mg BID x 10 days
Study NCT01140412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
Study NCT01140412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: maraviroc 300 mg QD x 5 days
Study NCT01140412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir
Description: fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study NCT01140412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Fosamprenavir/ritonavir
Description: maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
Study NCT03911362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic Stabilisation Exercises Group
Description: Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
Study NCT03911362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Exercises Group
Description: The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
Study NCT00494026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
Study NCT01512459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine MR Capsules 150 mg
Study NCT01512459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine MR Capsules 150 mg
Study NCT03577132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant atezolizumab
Description: Atezolimumab~* At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~* Every 3 weeks, for a total of 3 cycles prior to radical cystectomy
Study NCT02375828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
Study NCT03061799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HPC-03
Description: HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
Study NCT03061799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
Study NCT03111615 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aromatase Inhibitors
Description: Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated
Study NCT03111615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated
Study NCT03545269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CartiLife®
Description: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.
Study NCT03545269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.